Daphnetin
Catalog No: CFN99952
Daphnetin is a dihydroxycoumarin that is being used in China for the treatment of coagulation disorders, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit antimalarial, anti-rheumatoid arthritis, anti-proliferative, anti-inflammatory and anti-oxidant activities. it is also a chelator and an antioxidant. Daphnetin can enhance immunological functions of B lymphocytes, the expression of IL-12 in B lymphocytes can be up-regulated by daphnetin through natural immunity approach.
Parthenolide
Catalog No: CFN98034
Parthenolide exhibits anti-cancer, anti-inflammatory, immunomodulatory, anti-Leishmania, and antimigraine effects,
it inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Parthenolide is also an inhibitor of the nuclear factor-kappaB pathway, can ameliorate cardiovascular derangement and outcome in endotoxic shock in rodents.
Ginsenoside Rg1
Catalog No: CFN99967
Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA.
Ginsenoside Rd
Catalog No: CFN99975
Ginsenoside Rd, a minor ginseng saponin, has several pharmacological activities such as immunosuppressive activity, anti-inflammatory activity, immunological adjuvant, anti-cancer activity and wound-healing activity. Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Rd inhibits expression of COX-2 and iNOS mRNA. Rd also inhibits Ca2+ influx. Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
